By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abcodia today said that it will collaborate with Singapore-based VolitionRx on developing biomarker-based tests for a variety of cancers.

The London-based firm said that the partnership will discover and develop diagnostic tests for lung, colorectal, and pancreatic cancer using VolitionRx's nucleosome technology. Abcodia said that it will work with VolitonRx on designing the program and identifying cohort samples from its large prospective serum biobank.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.